The aim of this study is to systematically evaluate all available treatment options in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC). We systematically searched PubMed, EMBASE, and the Cochrane libraries up to 1 March 2016 for peer-reviewed publications on randomised clinical trials (RCTs). RCTs were included if progression-free survival (PFS), overall survival (OS), quality of life (QoL), or adverse events (AEs) were quantitatively evaluated. We assessed the risk of bias with the Cochrane Collaboration's tool and graded the evidence with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group's approach. We included 25 articles, reporting on 10 unique RCTs describing seven different comparisons. In one RCT, a prolonged OS and PFS (high quality) were found with abiraterone and prednisone compared to placebo plus prednisone. In one RCT, a prolonged OS and PFS (high quality) were found with enzalutamide compared to placebo. In two RCTs, a prolonged OS (high and moderate quality) was found with 223 radium compared to placebo, but its effect on PFS is unknown. In three RCTs, a prolonged OS (moderate quality) was found with sipuleucel-T compared to placebo, but no prolonged PFS (low quality). In one RCT a prolonged PFS (high quality) was found with orteronel compared to placebo, but no prolonged OS (moderate quality). In one RCT, a prolonged OS (moderate quality) was found with bicalutamide compared to placebo, but its effect on PFS is unknown. In one RCT, a prolonged PFS (high quality) was found with enzalutamide compared to bicalutamide, but its effect on OS is unknown. The best evidence was found for abiraterone and enzalutamide for effective prolongation of OS and PFS to treat chemotherapy-naive patients with mCRPC. However, taking both QoL and AEs into consideration, other treatment modalities could be considered for individual patients.
Introduction
Androgen responsive prostate cancer will progress into metastatic castration-resistant prostate cancer (mCRPC) despite usual care with androgen-deprivation therapy (ADT) or bilateral orchidectomy [1, 2] . Most patients show high initial response rates, but in the long term nearly all patients with prostate cancer develop CRPC characterised by an increase of serum PSA despite castrate levels of testosterone and the development of metastases [3] . Different therapeutic approaches have been suggested to improve the survival in patients with mCRPC. Chemotherapy with the taxane docetaxel or the semisynthetic taxane derivative cabazitaxel have been shown to prolong survival [4] [5] [6] . The use of cabazitaxel has not been reported yet as first-line treatment, whereas the use of mitoxantrone has been [7] . Nevertheless, the toxicity profiles of these chemotherapy regimens hamper
Search Strategy and Selection Criteria
We used the electronic databases PubMed, EMBASE, and the Cochrane library (including CDSR, DARE, and CENTRAL) from 2007 to 1 March 2016 (see Appendix S2 for the complete search strategy) to identify articles reporting original data written in English or Dutch, published in peer-reviewed journals, of RCTs comparing first-line treatment, including abiraterone, enzalutamide, 223 radium, sipuleucel-T, orteronel, or classic androgen receptor-blocker therapy, compared to placebo, prednisone, or each other in chemotherapy-naive patients with mCRPC. RCTs were included if one of the following outcomes was quantified: progression-free survival (PFS), overall survival (OS), quality of life (QoL), or adverse events (AEs). Abstracts or conference correspondence were excluded since a risk of bias (RoB) assessment could not be completely performed and these references have not been necessarily subject to a peer-reviewed evaluation. Two authors (M.H.F.P. and R.W.M.V.) screened titles and abstracts for eligible studies, and subsequently reviewed full-text versions of the potentially eligible studies (Appendix S3). We crosschecked the reference lists of identified SRs and included articles until no further eligible studies were found. In case of doubt, studies were discussed in consensus meetings. If multiple articles reported the data of one RCT, we collated the data so that each unique RCT was the unit of analysis. The outcomes of the final follow-up were used.
Data Extraction
Two authors (M.H.F.P. and R.W.M.V.) extracted the following study characteristics with the data collection form constructed by the CoCanCPG-group (www.cocancpg.eu): (i) Methods: study design, conflicts of interest, setting, sample size, duration of study, and existence of a protocol; (ii) Patient characteristics: eligibility criteria and baseline patient characteristics; (iii) Intervention: used intervention and comparator; (iv) Results outcomes: for continuous outcomes: mean or median, standard deviation (SD), and number of patients for both groups. For dichotomous outcomes: event rate and total number of patients for both groups. The data collection forms of all included studies can be found in Appendix S4.
Outcomes
The primary outcomes comprised: OS and (clinically or radiologically assessed) PFS. The secondary outcomes comprised: QoL, assessed with either the Functional Assessment of Cancer Therapy for patients with Prostate cancer (FACT-P) questionnaire or the EuroQol-5D (EQ-5D) questionnaire, and AEs, graded according to the Common Terminology Criteria for Adverse Events. Two authors (M.H.F.P. and R.W.M.V.) graded the quality of evidence on outcome level with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system to grade the quality of evidence. This includes a judgment regarding the RoB, directness of the evidence, heterogeneity in the data, precision of effect estimates, and risk of publication bias [14] . After the assessment of the evidence, the quality of evidence was categorised as 'high', 'moderate', 'low', or 'very low'. To construct evidence profiles we used the GRADE profiler software [15] .
Statistical Analysis
We analysed the effect of treatment with risk ratios (RRs) or odds ratios (ORs) for dichotomous outcomes, with hazard ratios (HRs) for time-dependent outcomes, and with mean differences for continuous data, presented with their corresponding 95% CIs. Statistical heterogeneity between the included studies was assessed by evaluating forest plots and by using the quantitative measurement of the I 2 test. We used the classification of heterogeneity of the Cochrane Collaboration [12] . A fixed effect meta-analysis was normally used whenever the included studies in the forest plot were functionally identical and whenever solely the identified population of interest was being investigated in the included studies. Whenever the I 2 test resulted in a score of <50% a fixed effect model was applied for the forest plot, when the score was between 50% and 75% a random effect model was used, and when the I 2 was >75% we did not pool the results of the included studies. All statistical analyses were conducted with Review Manager software [13] .
Results
After screening of 2 573 publications, 25 articles reporting the data of 10 unique RCTs were included in this SR (Fig. 1 ) . An overview of baseline demographic and clinical characteristics is provided in Table 1 . An overview of the outcomes is provided in Table 2 . The following results are reported per comparison.
Abiraterone Plus Prednisone vs Placebo Plus Prednisone
One study was identified that compared abiraterone plus prednisone with placebo plus prednisone [16] [17] [18] [19] [20] [21] . In the COU-AA-302 study, 1 088 chemotherapy-na€ ıve asymptomatic or mildly symptomatic patients without visceral metastases were randomly assigned to receive abiraterone acetate 1 000 mg daily plus prednisone 5 mg twice daily or placebo plus prednisone 5 mg twice daily. The median duration of follow-up was 49.2 months.
A significant difference in OS was found in favour of the abiraterone plus prednisone group with a HR for death of 0.81 (95% CI 0.70-0.93) [19] . Similarly, a significant difference in PFS was found in favour of abiraterone plus prednisone group with a HR of 0.52 (95% CI 0.45-0.61) [18] . All four outcomes were graded as a high quality of evidence (Table 3) .
Enzalutamide vs Placebo
One study was identified that compared enzalutamide with placebo [22, 23] . In the PREVAIL study, 1 717 chemotherapynaive asymptomatic or mildly symptomatic patients were randomly assigned to receive enzalutamide 160 mg daily or placebo daily; 12% of the included patients had visceral metastases. This study was stopped after the planned interim analysis, because of the observed benefit in the two coprimary outcomes OS and PFS. The median duration of follow-up was~22 months.
A significant difference in OS was found in favour of the enzalutamide group with a HR of 0.71 (95% CI 0.60-0.84) [22] . Similarly, a significant difference in PFS was found in favour of the enzalutamide group with a HR of 0.19 (95% CI 0.15-0.23) [22] .
Both the FACT-P and the EQ-5D scale were used to measure QoL. Patients treated with enzalutamide had significantly better scores on both scales [23] . This resulted in a RR of 1.73 (95% CI 1.48-2.01) measured by FACT-P and a RR of 1.74 (95% CI 1.40-2.15) measured by EQ-5D. There were more AEs in the enzalutamide group. In all, 43% of patients in the enzalutamide group had grade 3 or 4 AEs vs 37% of the patients in the placebo group [22] . This resulted in a RR of 1.16 (95% CI 1.03-1.30) in favour of the placebo group.
All four outcomes were graded as a high quality of evidence (Table 4) .
Radium vs Placebo
Two studies were identified that compared 223 radium with placebo [24] [25] [26] [27] [28] [29] [30] . In the ALSYMPCA study, 921 patients with two or more bone metastases and no known visceral metastases were randomly assigned to receive six injections of 223 radium or placebo [24] [25] [26] [27] [28] . This RCT included 526 (57%) patients with previous docetaxel use, and docetaxelnaive patients considered unfit for docetaxel. The planned duration of follow-up was 36 months. In the study of Nilsson et al. [29, 30] , 64 chemotherapy-naive patients with multiple bone metastases or one painful lesion with two consecutive rising amounts of PSA were randomly assigned In the subgroup of patients that did not previously receive docetaxel, no significant difference in OS was found. However, this was only visualised in a figure without quantified data. NC, not calculable. Both studies reported data on the OS. A significant difference in favour of the 223 radium group was found in OS in the subgroup analysis of patients without previous docetaxel use (that were unsuitable for or declined docetaxel) in the ALSYMPCA study with a HR of 0.69 (95% CI 0.52-0.92) [25] . However, the power is unproven, as the trial was not designed to compare 223 radium with placebo within this specific subgroup. Similarly, a significant effect in the study of Nilsson et al. [29, 30] was found, with a HR of 0.48 (95% CI 0.26-0.88). We were not able to meta-analyse these data, as the study of Nilsson et al. did not provide values of variance (e.g. SD or 95% CI). Both studies did not report data on PFS.
Both the FACT-P and the EQ-5D scale were used to measure QoL in the intent-to-treat population in the ALSYMPCA study [28] . For the FACT-P, an improvement at 24 weeks in total score was found in 18.2% (57/314) of the patients treated with 223 radium and in 8.3% (10/120) of the patients treated with placebo [28] . This resulted in a RR of 2.18 (95% CI 1.15-4.12). For the EQ-5D, an improvement at 24 weeks in total score was found in 21.9% (75/343) of the patients treated with 223 radium and in 15.3% (20/131) of the patients treated with placebo [28] . This resulted in a RR of 1.43 (95% CI 0.91-2.25). The study of Nilsson et al. [29, 30] did not report on QoL.
The ALSYMPCA study measured grade 3 or 4 AEs in the intent-to-treat population and Nilsson et al. [29, 30] Although, both studies reported data on AEs, it was not possible to pool the data, due to the difference in the definition of measuring AEs.
The outcomes of OS and QoL in the ALSYMPCA study were graded as a high quality of evidence. The outcomes of AEs in the ALSYMPCA study and OS in the study of Nilsson et al. [29, 30] were downgraded to a moderate quality of evidence, because relatively few patients were included in the study and the CI includes two different directions, respectively. Similarly, the outcomes of AEs and serious AEs in the study of Nilsson et al. [29, 30] were downgraded to a low quality of evidence, because relatively few patients were included and no blinding after 12 months (total follow-up 24 months) was performed, respectively (Table 5) .
Sipuleucel-T vs Placebo
Three studies were identified that compared sipuleucel-T with placebo [31] [32] [33] [34] . In all studies, patients were randomly assigned to receive sipuleucel-T every 2 weeks with a total of three infusions or placebo. In the IMPACT study, 512 asymptomatic or mildly symptomatic patients without visceral metastases were included [31] . This RCT included 19.6% patients post-chemotherapy in the sipuleucel-T group. The median duration of follow-up was 34.1 months. Small et al. [34] included 127 patients in the D9901 study. Higano et al. [33] integrated the data of the D9901 study with the identical small phase 3 trial D9902A. In all, 225 patients with radiological evidence of metastases, with a ≥ 3 months chemotherapy-free interval, and no visceral metastases or pain from bone metastases were included [33] . The duration of follow-up was not reported.
In the IMPACT study, a significant difference in OS in favour of the sipuleucel-T group was found with a HR of 0.78 (95% CI 0.61-0.98) [31] . In the subgroup of patients that did not previously receive docetaxel, no significant difference in OS was found. However, this was only visualised in a figure without quantified data. No significant difference in PFS was found. In the IMPACT study, the median time to objective disease progression was 14.6 weeks in the sipuleucel-T group and 14.4 weeks in the placebo group, resulting in a HR of 0.95 (95% CI 0.77-1.17) [31] . No significant difference in clinical disease progression was found, with a HR of 0.92 (95% CI 0.75-1.12) [31] . In the D9901 and D9902A studies, the median OS was 23.2 months in the sipuleucel-T group and 18.9 months in the placebo group with a HR of 1.50 (95% CI 1.10-2.05) [33] . In the D9901 and D9902A studies, the median time to progression was 11.1 weeks in the sipuleucel-T group and 9.7 weeks in the placebo group with in a HR of 1.26 (95% CI 0.95-1.68) [33] .
In the D9901 and D9902A studies, the HR is defined as the risk in patients treated with placebo divided by the risk in patients treated with sipuleucel-T. Therefore, a HR of ≥1 indicates a higher risk for patients treated with placebo relative to sipuleucel-T. Consequently, a pooled analysis of the HRs of the three studies is not possible. (Fig. 2) .
The outcome of PFS was downgraded to a low quality of evidence, because no description of randomisation, allocation concealment, blinding, and selective outcome reporting was provided. The outcome AEs was downgraded to a low quality of evidence, because the CI included two different directions. The outcome OS was downgraded to a moderate quality of evidence, because no description of randomisation, allocation concealment, blinding, and selective outcome reporting was provided (Table 6 ).
Orteronel Plus Prednisone vs Placebo Plus Prednisone
One study was identified that compared orteronel with placebo [35] . In the ELM-PC4 study, 1 560 chemotherapynaive patients with radiographic nodal, bone or visceral metastases were randomly assigned to receive orteronel 400 mg daily plus prednisone 5 mg twice daily or placebo plus prednisone 5 mg twice daily [35] . The median duration of follow-up was 20.7 months.
No significant difference in OS was found, with a HR of 0.92 (95% CI 0.79-1.08) [35] . A significant difference in radiographic PFS was found, with a HR of 0.71 (95% CI 0.63-0.80) [35] . The outcomes of PFS and AEs were graded as a high quality of evidence. The outcome of OS was downgraded to a moderate quality of evidence, because the effect between the control and intervention group did not differ significantly.
Consequently, recommendations about the use of the intervention can differ between the lower and upper limit of the CI (Table 7) .
Bicalutamide vs Placebo
One study was identified that compared bicalutamide with placebo [36] [37] [38] [39] . In this RCT, 203 chemotherapy-naive patients were randomly assigned to receive bicalutamide 80 mg daily or placebo. The median duration of follow-up was 62.4 months.
A significant difference in OS was found, with a HR of 0.78 (95% CI 0.60-0.99) in favour of the bicalutamide group [39] . No data on PFS were reported.
The FACT-P was used to measure QoL [38] . No significant difference between the bicalutamide and placebo group was found in the improvement at 24 weeks compared to baseline. No data on AEs were reported.
The outcome of OS was graded as a moderate quality of evidence, as no details about randomisation, blinding, and allocation were provided. The outcome of QoL was downgraded to a low quality of evidence, because no details about randomisation, blinding, and allocation were provided. Next to that, no risk estimate could be calculated hampering the evaluation of size and direction of the effect (Table 8) .
Bicalutamide vs Enzalutamide
One study was identified that compared bicalutamide with enzalutamide [40] . In the TERRAIN study, 375 asymptomatic or mildly symptomatic patients with at least two bone lesions or soft tissue metastases were randomly assigned to receive bicalutamide 50 mg daily or enzalutamide 160 mg daily [40] . The median duration of follow-up was 16.7 months in the bicalutamide group and 20.0 months in the enzalutamide group.
No data on OS were reported. A significant difference in PFS was found, with a HR of 0.44 (95% CI 0.34-0.57) [40] .
The FACT-P was used to measure QoL. In all, 22% of the patients in the enzalutamide group and 33% of the patients in the bicalutamide group had improvement at any time during the study [40] . No risk estimate was reported and we were not able to calculate a risk estimate. Continuous outcomes are not provided in the studies and HRs of the two studies could not be pooled, because in the IMPACT study, the risk estimate was defined as the risk in patients treated with sipuleucel-T divided by the risk in patients treated with placebo and in the D9901 and D9902A studies, the risk estimate was defined as the risk in patients treated with placebo divided by the risk in patients treated with sipuleucel-T. *The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). GRADE Working Group grades of evidence: High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.
the bicalutamide group had AEs [40] . This resulted in a RR of 1.05 (95% CI 0.81-1.35).
The outcome of PFS was graded as a high quality of evidence. The outcome QoL was graded as a moderate quality of evidence, because the upper and lower limit of the CI indicate different directions (Table 9 ).
Discussion
In this SR, 10 unique RCTs reporting on seven different comparisons, assessing the efficacy and safety of first-line therapy for chemotherapy-naive patients with mCRPC, were included. To summarise, the best available evidence for the outcomes OS and PFS was found for abiraterone plus prednisone and for enzalutamide.
223
Radium and bicalutamide showed a prolonged OS, but their effect on PFS is unknown. Sipuleucel-T showed a prolonged OS, but no effect on PFS. Orteronel showed a prolonged PFS, but no effect on OS. PFS was prolonged with enzalutamide compared to bicalutamide, but its effect on OS is unknown. The critical appraisal of study quality, differences in selection of patients in the RCTs, QoL, and AEs should be considered when treatment possibilities are discussed with patients once they develop mCRPC. ⊕⊕⊕⊕ high *The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). † Lower interval of the CI results in different conclusion than the upper limit. GRADE Working Group grades of evidence: High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. 
Appropriate Selection of Patients
Selection of patients is a challenge, especially, as guidance for treatment decisions by clinically validated prognostic characteristics are not available [8] . The TERRAIN study compared enzalutamide with bicalutamide, but all other RCTs compared the experimental agent to placebo and/or prednisone.
Differences in selection of patients and varying subgroup effects in the RCTs can indirectly inform treatment decisions. The COU-AA-302 study, PREVAIL study and TERRAIN study restricted inclusion to asymptomatic and minimally symptomatic docetaxel-naive patients, establishing the role of separate treatment with enzalutamide or abiraterone in the pre-chemotherapy setting. The addition of abiraterone in patients treated with enzalutamide is currently under investigation in the phase III ALLIANCE study (NCT01949337). In addition, in the PREVAIL study, 204 of the 1 717 (12%) included patients had visceral metastases. In those patients, a trend was seen towards an increase in OS in patients treated with enzalutamide compared to placebo with a HR of 0.82 (95% CI 0.55-1.23).
The role of orteronel is less established, because, although radiographic PFS was prolonged, no OS benefit was found in the ELM-PC4 study [35] . Only patients with a PSA level of >50 ng/mL at baseline showed a significantly prolonged OS [35] . The ELM-PC4 study included 277 of 1 560 (17.8%) patients with visceral metastases [35] . However, the effect of treatment with orteronel was not measured separately for these patients. Based on these clinical data the company decided to stop the development of orteronel in June 2014.
The ALSYMPCA study included patients that were either pretreated with docetaxel or were unsuitable for or declined docetaxel. Moreover, most of the patients had more than six symptomatic bone metastases. The role of 223 radium is therefore at this moment only proven for the defined group of patients that had already received docetaxel. For this reason, the National Institute for Health and Care Excellence (NICE) has not recommended 223 radium in docetaxel-naive patients [41] . The role of 223 radium in addition to abiraterone or enzalutamide for a broader indication is currently being investigated in a phase III trial (NCT02043678), as is optimisation of the dosing schedule in a phase II trial (NCT0203697).
In the first two trials comparing sipuleucel-T to placebo, a significant prolongation of OS was found, but no benefit in terms of PFS. Similar results were found in the IMPACT trial. Based on the OS benefit, sipuleucel-T was approved by the USA Food and Drug Administration (FDA), but it is not available in Europe [1, 2, 42] .
Sequence and Combination of Different Treatment Options
The efficacy and safety of the sequential use of different treatment options is a clinical important question, which remains to be answered and cannot be solved by the present analysis. Sipuleucel-T has been proposed for early stages of mCRPC, as patients with lower PSA levels are more likely to benefit from sipuleucel-T [8, 32, 43] . Data from observational studies suggests cross-resistance between enzalutamide and abiraterone [44] [45] [46] . A ≥ 50% decline in PSA level was found in 18-34% of the patients treated with enzalutamide after abiraterone, but without prior docetaxel treatment. Based on expert consensus and available evidence at this moment, enzalutamide should not be considered after progression on abiraterone due to cross-resistance [43] . Although data from small observational studies suggest reduced activity of docetaxel after abiraterone, docetaxel is still recommended in patients with progression after abiraterone [8, 9, [47] [48] [49] [50] .
Starting enzalutamide in addition to abiraterone after progression on abiraterone is currently being investigated in the PLATO study (NCT01995513). No evidence is available for starting abiraterone after progression on enzalutamide. In the PRESIDE study (NCT02288247), the continuation of enzalutamide in patients starting with docetaxel is currently being investigated, and in the ERA 223 study (NCT02043678) 223 radium and abiraterone are compared to abiraterone alone in patients with asymptomatic or mildly symptomatic mCRPC.
Strengths and Limitations
The strength of our present SR and meta-analysis is its extensive and comprehensive literature search and overview of all available data on different available treatment options for patients with mCRPC without previous chemotherapeutic treatment [51, 52] . In addition, we assessed the RoB and quality of evidence according to relevant standards. Finally, we were able to pool data of the outcome of AEs from three different studies reporting on the comparison sipuleucel-T vs placebo. However, we were not able to pool data for other comparisons, as we were cautious of comparing the heterogeneous terminology and methodology of the included studies. In addition, only non-cytotoxic treatment options were included in the present SR. Consequently, the role and timing of the initiation of docetaxel in patients with mCRPC needs further clarification. Additionally, publication bias might be a threat to the review's validity, as some studies might be poorly indexed or not identified by our systematic search.
Implications for Future Research
Our present SR has implications for future research, as the identification of subgroups remains challenging in the current therapeutic landscape for patients with mCRPC. On the one hand, subgroups are underrepresented in the available studies, as is the case with patients with visceral metastases. On the other hand, characteristics that can help in guiding the appropriate treatment are largely unknown. Further research is needed to identify subgroups for which certain treatment options are beneficial for OS and PFS without decreasing the QoL and with acceptable AEs. Selective reporting of these outcomes hampers weighing the benefits and harms of treatment options. Finally, further research is needed to identify patients that are not eligible for pre-docetaxel treatment, as postponing of chemotherapy could reduce their OS or PFS.
Conclusion
The best evidence for effective prolongation of OS and PFS in chemotherapy-naive patients with mCRPC was found for abiraterone plus prednisone and enzalutamide. In two RCTs that compared 223 radium to placebo a prolonged OS considered of high quality in one and of moderate quality in the other was found in patients treated with 223 radium, but the effect of 223 radium on PFS is unknown. In three RCTs that compared sipuleucel-T to placebo a prolonged OS considered of moderate quality was found in patients treated with sipuleucel-T, but the PFS considered of low quality was not prolonged. In one RCT that compared orteronel with placebo, a prolonged PFS considered of high quality was found in patients treated with orteronel, but OS considered of moderate quality was not prolonged. In one RCT that compared bicalutamide to placebo, a prolonged OS considered of moderate quality was found in patients treated with bicalutamide, but the effect of bicalutamide on PFS is unknown. In one RCT that compared bicalutamide to enzalutamide, a prolonged PFS considered of high quality was found in patients treated with enzalutamide, but the effect on OS is unknown. Treatment options besides enzalutamide and abiraterone plus prednisone could be considered for individual patients by taking the quality of the studies, selection of patients, and both the QoL and AEs into consideration. The sequence and combination of treatment options in chemotherapy-naive patients with mCRPC remain a clinical challenge.
